Open- | Close- |
Vol / Avg.0 / 356.266K | Mkt Cap1.381B |
Day Range- - - | 52 Wk Range21.070 - 31.860 |
Agios Pharmaceuticals Stock (NASDAQ: AGIO) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.0 / 356.266K | Mkt Cap1.381B |
Day Range- - - | 52 Wk Range21.070 - 31.860 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.690 | (EXPECTED) 2023-11-02 | |||||
REV | 7.910M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.600 | -1.510 | 0.0900 | ||||
REV | 6.670M | 6.712M | 42.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-07 | JP Morgan | Tessa Romero | Maintains | NeutralNeutral | Lowers | 33.00 | 32.00 |
2023-06-27 | RBC Capital | Kennen MacKay | Maintains | OutperformOutperform | Raises | 40.00 | 42.00 |
2023-02-03 | Piper Sandler | Christopher Raymond | Initiates Coverage On | Overweight | Announces | - | 41.00 |
2022-12-01 | JP Morgan | Tessa Romero | Maintains | Neutral | Lowers | 48.00 | 33.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
AGIO | Agios Pharmaceuticals | 0% | 1.4B |
IDYA | IDEAYA Biosciences | 0% | 1.5B |
ZNTL | Zentalis Pharma | 0% | 1.4B |
SAGE | Sage Therapeutics | 0% | 1.2B |
XNCR | Xencor | 0% | 1.2B |
You can purchase shares of Agios Pharmaceuticals (NASDAQ: AGIO) through any online brokerage.
Other companies in Agios Pharmaceuticals’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Zentalis Pharma (NASDAQ:ZNTL), Sage Therapeutics (NASDAQ:SAGE), Xencor (NASDAQ:XNCR) and SpringWorks Therapeutics (NASDAQ:SWTX).
The latest price target for Agios Pharmaceuticals (NASDAQ: AGIO) was reported by JP Morgan on Monday, August 7, 2023. The analyst firm set a price target for 32.00 expecting AGIO to rise to within 12 months (a possible 29.19% upside). 5 analyst firms have reported ratings in the last year.
The stock price for Agios Pharmaceuticals (NASDAQ: AGIO) is $24.77 last updated September 28, 2023 at 8:00 PM UTC.
There is no dividend information for Agios Pharmaceuticals.
Agios Pharmaceuticals’s Q3 earnings are confirmed for Thursday, November 2, 2023.
There is no upcoming split for Agios Pharmaceuticals.
Agios Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Agios Pharmaceuticals Stock (NASDAQ: AGIO) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.0 / 356.266K | Mkt Cap1.381B |
Day Range- - - | 52 Wk Range21.070 - 31.860 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.690 | (EXPECTED) 2023-11-02 | |||||
REV | 7.910M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.600 | -1.510 | 0.0900 | ||||
REV | 6.670M | 6.712M | 42.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-07 | JP Morgan | Tessa Romero | Maintains | NeutralNeutral | Lowers | 33.00 | 32.00 |
2023-06-27 | RBC Capital | Kennen MacKay | Maintains | OutperformOutperform | Raises | 40.00 | 42.00 |
2023-02-03 | Piper Sandler | Christopher Raymond | Initiates Coverage On | Overweight | Announces | - | 41.00 |
2022-12-01 | JP Morgan | Tessa Romero | Maintains | Neutral | Lowers | 48.00 | 33.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
AGIO | Agios Pharmaceuticals | 0% | 1.4B |
IDYA | IDEAYA Biosciences | 0% | 1.5B |
ZNTL | Zentalis Pharma | 0% | 1.4B |
SAGE | Sage Therapeutics | 0% | 1.2B |
XNCR | Xencor | 0% | 1.2B |
You can purchase shares of Agios Pharmaceuticals (NASDAQ: AGIO) through any online brokerage.
Other companies in Agios Pharmaceuticals’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Zentalis Pharma (NASDAQ:ZNTL), Sage Therapeutics (NASDAQ:SAGE), Xencor (NASDAQ:XNCR) and SpringWorks Therapeutics (NASDAQ:SWTX).
The latest price target for Agios Pharmaceuticals (NASDAQ: AGIO) was reported by JP Morgan on Monday, August 7, 2023. The analyst firm set a price target for 32.00 expecting AGIO to rise to within 12 months (a possible 29.19% upside). 5 analyst firms have reported ratings in the last year.
The stock price for Agios Pharmaceuticals (NASDAQ: AGIO) is $24.77 last updated September 28, 2023 at 8:00 PM UTC.
There is no dividend information for Agios Pharmaceuticals.
Agios Pharmaceuticals’s Q3 earnings are confirmed for Thursday, November 2, 2023.
There is no upcoming split for Agios Pharmaceuticals.
Agios Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Agios Pharmaceuticals Stock (NASDAQ: AGIO) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.0 / 356.266K | Mkt Cap1.381B |
Day Range- - - | 52 Wk Range21.070 - 31.860 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.690 | (EXPECTED) 2023-11-02 | |||||
REV | 7.910M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.600 | -1.510 | 0.0900 | ||||
REV | 6.670M | 6.712M | 42.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-07 | JP Morgan | Tessa Romero | Maintains | NeutralNeutral | Lowers | 33.00 | 32.00 |
2023-06-27 | RBC Capital | Kennen MacKay | Maintains | OutperformOutperform | Raises | 40.00 | 42.00 |
2023-02-03 | Piper Sandler | Christopher Raymond | Initiates Coverage On | Overweight | Announces | - | 41.00 |
2022-12-01 | JP Morgan | Tessa Romero | Maintains | Neutral | Lowers | 48.00 | 33.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
AGIO | Agios Pharmaceuticals | 0% | 1.4B |
IDYA | IDEAYA Biosciences | 0% | 1.5B |
ZNTL | Zentalis Pharma | 0% | 1.4B |
SAGE | Sage Therapeutics | 0% | 1.2B |
XNCR | Xencor | 0% | 1.2B |
You can purchase shares of Agios Pharmaceuticals (NASDAQ: AGIO) through any online brokerage.
Other companies in Agios Pharmaceuticals’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Zentalis Pharma (NASDAQ:ZNTL), Sage Therapeutics (NASDAQ:SAGE), Xencor (NASDAQ:XNCR) and SpringWorks Therapeutics (NASDAQ:SWTX).
The latest price target for Agios Pharmaceuticals (NASDAQ: AGIO) was reported by JP Morgan on Monday, August 7, 2023. The analyst firm set a price target for 32.00 expecting AGIO to rise to within 12 months (a possible 29.19% upside). 5 analyst firms have reported ratings in the last year.
The stock price for Agios Pharmaceuticals (NASDAQ: AGIO) is $24.77 last updated September 28, 2023 at 8:00 PM UTC.
There is no dividend information for Agios Pharmaceuticals.
Agios Pharmaceuticals’s Q3 earnings are confirmed for Thursday, November 2, 2023.
There is no upcoming split for Agios Pharmaceuticals.
Agios Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Agios Pharmaceuticals Stock (NASDAQ: AGIO) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.0 / 356.266K | Mkt Cap1.381B |
Day Range- - - | 52 Wk Range21.070 - 31.860 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.690 | (EXPECTED) 2023-11-02 | |||||
REV | 7.910M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.600 | -1.510 | 0.0900 | ||||
REV | 6.670M | 6.712M | 42.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-07 | JP Morgan | Tessa Romero | Maintains | NeutralNeutral | Lowers | 33.00 | 32.00 |
2023-06-27 | RBC Capital | Kennen MacKay | Maintains | OutperformOutperform | Raises | 40.00 | 42.00 |
2023-02-03 | Piper Sandler | Christopher Raymond | Initiates Coverage On | Overweight | Announces | - | 41.00 |
2022-12-01 | JP Morgan | Tessa Romero | Maintains | Neutral | Lowers | 48.00 | 33.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
AGIO | Agios Pharmaceuticals | 0% | 1.4B |
IDYA | IDEAYA Biosciences | 0% | 1.5B |
ZNTL | Zentalis Pharma | 0% | 1.4B |
SAGE | Sage Therapeutics | 0% | 1.2B |
XNCR | Xencor | 0% | 1.2B |
You can purchase shares of Agios Pharmaceuticals (NASDAQ: AGIO) through any online brokerage.
Other companies in Agios Pharmaceuticals’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Zentalis Pharma (NASDAQ:ZNTL), Sage Therapeutics (NASDAQ:SAGE), Xencor (NASDAQ:XNCR) and SpringWorks Therapeutics (NASDAQ:SWTX).
The latest price target for Agios Pharmaceuticals (NASDAQ: AGIO) was reported by JP Morgan on Monday, August 7, 2023. The analyst firm set a price target for 32.00 expecting AGIO to rise to within 12 months (a possible 29.19% upside). 5 analyst firms have reported ratings in the last year.
The stock price for Agios Pharmaceuticals (NASDAQ: AGIO) is $24.77 last updated September 28, 2023 at 8:00 PM UTC.
There is no dividend information for Agios Pharmaceuticals.
Agios Pharmaceuticals’s Q3 earnings are confirmed for Thursday, November 2, 2023.
There is no upcoming split for Agios Pharmaceuticals.
Agios Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Agios Pharmaceuticals Stock (NASDAQ: AGIO) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.0 / 356.266K | Mkt Cap1.381B |
Day Range- - - | 52 Wk Range21.070 - 31.860 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.690 | (EXPECTED) 2023-11-02 | |||||
REV | 7.910M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.600 | -1.510 | 0.0900 | ||||
REV | 6.670M | 6.712M | 42.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-07 | JP Morgan | Tessa Romero | Maintains | NeutralNeutral | Lowers | 33.00 | 32.00 |
2023-06-27 | RBC Capital | Kennen MacKay | Maintains | OutperformOutperform | Raises | 40.00 | 42.00 |
2023-02-03 | Piper Sandler | Christopher Raymond | Initiates Coverage On | Overweight | Announces | - | 41.00 |
2022-12-01 | JP Morgan | Tessa Romero | Maintains | Neutral | Lowers | 48.00 | 33.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
AGIO | Agios Pharmaceuticals | 0% | 1.4B |
IDYA | IDEAYA Biosciences | 0% | 1.5B |
ZNTL | Zentalis Pharma | 0% | 1.4B |
SAGE | Sage Therapeutics | 0% | 1.2B |
XNCR | Xencor | 0% | 1.2B |
You can purchase shares of Agios Pharmaceuticals (NASDAQ: AGIO) through any online brokerage.
Other companies in Agios Pharmaceuticals’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Zentalis Pharma (NASDAQ:ZNTL), Sage Therapeutics (NASDAQ:SAGE), Xencor (NASDAQ:XNCR) and SpringWorks Therapeutics (NASDAQ:SWTX).
The latest price target for Agios Pharmaceuticals (NASDAQ: AGIO) was reported by JP Morgan on Monday, August 7, 2023. The analyst firm set a price target for 32.00 expecting AGIO to rise to within 12 months (a possible 29.19% upside). 5 analyst firms have reported ratings in the last year.
The stock price for Agios Pharmaceuticals (NASDAQ: AGIO) is $24.77 last updated September 28, 2023 at 8:00 PM UTC.
There is no dividend information for Agios Pharmaceuticals.
Agios Pharmaceuticals’s Q3 earnings are confirmed for Thursday, November 2, 2023.
There is no upcoming split for Agios Pharmaceuticals.
Agios Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Agios Pharmaceuticals Stock (NASDAQ: AGIO) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.0 / 356.266K | Mkt Cap1.381B |
Day Range- - - | 52 Wk Range21.070 - 31.860 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.690 | (EXPECTED) 2023-11-02 | |||||
REV | 7.910M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.600 | -1.510 | 0.0900 | ||||
REV | 6.670M | 6.712M | 42.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-07 | JP Morgan | Tessa Romero | Maintains | NeutralNeutral | Lowers | 33.00 | 32.00 |
2023-06-27 | RBC Capital | Kennen MacKay | Maintains | OutperformOutperform | Raises | 40.00 | 42.00 |
2023-02-03 | Piper Sandler | Christopher Raymond | Initiates Coverage On | Overweight | Announces | - | 41.00 |
2022-12-01 | JP Morgan | Tessa Romero | Maintains | Neutral | Lowers | 48.00 | 33.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
AGIO | Agios Pharmaceuticals | 0% | 1.4B |
IDYA | IDEAYA Biosciences | 0% | 1.5B |
ZNTL | Zentalis Pharma | 0% | 1.4B |
SAGE | Sage Therapeutics | 0% | 1.2B |
XNCR | Xencor | 0% | 1.2B |
You can purchase shares of Agios Pharmaceuticals (NASDAQ: AGIO) through any online brokerage.
Other companies in Agios Pharmaceuticals’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Zentalis Pharma (NASDAQ:ZNTL), Sage Therapeutics (NASDAQ:SAGE), Xencor (NASDAQ:XNCR) and SpringWorks Therapeutics (NASDAQ:SWTX).
The latest price target for Agios Pharmaceuticals (NASDAQ: AGIO) was reported by JP Morgan on Monday, August 7, 2023. The analyst firm set a price target for 32.00 expecting AGIO to rise to within 12 months (a possible 29.19% upside). 5 analyst firms have reported ratings in the last year.
The stock price for Agios Pharmaceuticals (NASDAQ: AGIO) is $24.77 last updated September 28, 2023 at 8:00 PM UTC.
There is no dividend information for Agios Pharmaceuticals.
Agios Pharmaceuticals’s Q3 earnings are confirmed for Thursday, November 2, 2023.
There is no upcoming split for Agios Pharmaceuticals.
Agios Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Agios Pharmaceuticals Stock (NASDAQ: AGIO) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.0 / 356.266K | Mkt Cap1.381B |
Day Range- - - | 52 Wk Range21.070 - 31.860 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.690 | (EXPECTED) 2023-11-02 | |||||
REV | 7.910M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.600 | -1.510 | 0.0900 | ||||
REV | 6.670M | 6.712M | 42.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-07 | JP Morgan | Tessa Romero | Maintains | NeutralNeutral | Lowers | 33.00 | 32.00 |
2023-06-27 | RBC Capital | Kennen MacKay | Maintains | OutperformOutperform | Raises | 40.00 | 42.00 |
2023-02-03 | Piper Sandler | Christopher Raymond | Initiates Coverage On | Overweight | Announces | - | 41.00 |
2022-12-01 | JP Morgan | Tessa Romero | Maintains | Neutral | Lowers | 48.00 | 33.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
AGIO | Agios Pharmaceuticals | 0% | 1.4B |
IDYA | IDEAYA Biosciences | 0% | 1.5B |
ZNTL | Zentalis Pharma | 0% | 1.4B |
SAGE | Sage Therapeutics | 0% | 1.2B |
XNCR | Xencor | 0% | 1.2B |
You can purchase shares of Agios Pharmaceuticals (NASDAQ: AGIO) through any online brokerage.
Other companies in Agios Pharmaceuticals’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Zentalis Pharma (NASDAQ:ZNTL), Sage Therapeutics (NASDAQ:SAGE), Xencor (NASDAQ:XNCR) and SpringWorks Therapeutics (NASDAQ:SWTX).
The latest price target for Agios Pharmaceuticals (NASDAQ: AGIO) was reported by JP Morgan on Monday, August 7, 2023. The analyst firm set a price target for 32.00 expecting AGIO to rise to within 12 months (a possible 29.19% upside). 5 analyst firms have reported ratings in the last year.
The stock price for Agios Pharmaceuticals (NASDAQ: AGIO) is $24.77 last updated September 28, 2023 at 8:00 PM UTC.
There is no dividend information for Agios Pharmaceuticals.
Agios Pharmaceuticals’s Q3 earnings are confirmed for Thursday, November 2, 2023.
There is no upcoming split for Agios Pharmaceuticals.
Agios Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Agios Pharmaceuticals Stock (NASDAQ: AGIO) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.0 / 356.266K | Mkt Cap1.381B |
Day Range- - - | 52 Wk Range21.070 - 31.860 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.690 | (EXPECTED) 2023-11-02 | |||||
REV | 7.910M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.600 | -1.510 | 0.0900 | ||||
REV | 6.670M | 6.712M | 42.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-07 | JP Morgan | Tessa Romero | Maintains | NeutralNeutral | Lowers | 33.00 | 32.00 |
2023-06-27 | RBC Capital | Kennen MacKay | Maintains | OutperformOutperform | Raises | 40.00 | 42.00 |
2023-02-03 | Piper Sandler | Christopher Raymond | Initiates Coverage On | Overweight | Announces | - | 41.00 |
2022-12-01 | JP Morgan | Tessa Romero | Maintains | Neutral | Lowers | 48.00 | 33.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
AGIO | Agios Pharmaceuticals | 0% | 1.4B |
IDYA | IDEAYA Biosciences | 0% | 1.5B |
ZNTL | Zentalis Pharma | 0% | 1.4B |
SAGE | Sage Therapeutics | 0% | 1.2B |
XNCR | Xencor | 0% | 1.2B |
You can purchase shares of Agios Pharmaceuticals (NASDAQ: AGIO) through any online brokerage.
Other companies in Agios Pharmaceuticals’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Zentalis Pharma (NASDAQ:ZNTL), Sage Therapeutics (NASDAQ:SAGE), Xencor (NASDAQ:XNCR) and SpringWorks Therapeutics (NASDAQ:SWTX).
The latest price target for Agios Pharmaceuticals (NASDAQ: AGIO) was reported by JP Morgan on Monday, August 7, 2023. The analyst firm set a price target for 32.00 expecting AGIO to rise to within 12 months (a possible 29.19% upside). 5 analyst firms have reported ratings in the last year.
The stock price for Agios Pharmaceuticals (NASDAQ: AGIO) is $24.77 last updated September 28, 2023 at 8:00 PM UTC.
There is no dividend information for Agios Pharmaceuticals.
Agios Pharmaceuticals’s Q3 earnings are confirmed for Thursday, November 2, 2023.
There is no upcoming split for Agios Pharmaceuticals.
Agios Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Agios Pharmaceuticals Stock (NASDAQ: AGIO) stock price, news, charts, stock research, profile.
Open- | Close- |
Vol / Avg.0 / 356.266K | Mkt Cap1.381B |
Day Range- - - | 52 Wk Range21.070 - 31.860 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.690 | (EXPECTED) 2023-11-02 | |||||
REV | 7.910M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.600 | -1.510 | 0.0900 | ||||
REV | 6.670M | 6.712M | 42.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-07 | JP Morgan | Tessa Romero | Maintains | NeutralNeutral | Lowers | 33.00 | 32.00 |
2023-06-27 | RBC Capital | Kennen MacKay | Maintains | OutperformOutperform | Raises | 40.00 | 42.00 |
2023-02-03 | Piper Sandler | Christopher Raymond | Initiates Coverage On | Overweight | Announces | - | 41.00 |
2022-12-01 | JP Morgan | Tessa Romero | Maintains | Neutral | Lowers | 48.00 | 33.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
AGIO | Agios Pharmaceuticals | 0% | 1.4B |
IDYA | IDEAYA Biosciences | 0% | 1.5B |
ZNTL | Zentalis Pharma | 0% | 1.4B |
SAGE | Sage Therapeutics | 0% | 1.2B |
XNCR | Xencor | 0% | 1.2B |
You can purchase shares of Agios Pharmaceuticals (NASDAQ: AGIO) through any online brokerage.
Other companies in Agios Pharmaceuticals’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Zentalis Pharma (NASDAQ:ZNTL), Sage Therapeutics (NASDAQ:SAGE), Xencor (NASDAQ:XNCR) and SpringWorks Therapeutics (NASDAQ:SWTX).
The latest price target for Agios Pharmaceuticals (NASDAQ: AGIO) was reported by JP Morgan on Monday, August 7, 2023. The analyst firm set a price target for 32.00 expecting AGIO to rise to within 12 months (a possible 29.19% upside). 5 analyst firms have reported ratings in the last year.
The stock price for Agios Pharmaceuticals (NASDAQ: AGIO) is $24.77 last updated September 28, 2023 at 8:00 PM UTC.
There is no dividend information for Agios Pharmaceuticals.
Agios Pharmaceuticals’s Q3 earnings are confirmed for Thursday, November 2, 2023.
There is no upcoming split for Agios Pharmaceuticals.
Agios Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.